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Abstract  
Purpose: The goal of this study was to determine if a pharmacist-led intervention to improve medication safety at hospital discharge 
reduced the number of hospital readmissions among geriatric high-utilizer patients. This study is the first to test a pharmacist-based 
intervention in a high-utilizer population. 
Methods: This was a quasi-experimental pilot study done at a safety-net hospital in the southeastern US. Fifty-seven patients 65 years 
old and older who were in the 95th percentile for number of hospital admissions in a year were included. On the day of discharge, one 
of the study pharmacists reviewed the discharge medication list and calculated the Medication Appropriateness Index (MAI) for each 
medication and reviewed for Beers Criteria. Any medication identified as potentially high-risk or inappropriate was flagged by the 
pharmacist and discussed with the team. The primary outcome was the number of admissions in the year following the intervention in 
the intervention group versus the control group. 
Results: There were no statistically significant differences in the number of admissions, the MAI scores, or the number of medications 
meeting Beers Criteria between the two groups. 
Conclusion: Although this study did not demonstrate a decrease in hospital admissions, it shows that pharmacist review of medications 
at discharge can identify potentially unnecessary medications that could lead to confusion or adverse events. Further research is 
necessary to identify interventions to prevent readmissions in this high-risk population. 
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Introduction  
In 2015, health care accounted for 17.8% of the U.S.’ $18.5 
trillion economy(1), and in the next eight years it is expected to 
rise to nearly 20%(2). Strikingly, 50% of health care costs are 
generated by only 5% of patients(2,3). Though the population 
of high utilizers is very heterogeneous, they are more likely to 
be older, less educated, and publicly insured(4-6). Many have 
markedly worse outcomes than their peers, despite receiving 
more health care(6-8). These patients are of great interest to 
stakeholders at all levels, including physicians, hospital 
administrators, public (Medicare, Medicaid) and private 
payers, and policy makers.    
 
Polypharmacy, while an important marker of health and 
intensity of medical care, does not tell the whole story. High-
risk medications are a known contributor to adverse events and 
short-term (≤30-day) readmissions in elderly patients(9). 
However, it is not known how much they contribute to 
readmission risk beyond thirty days. While long-term 
readmissions are not penalized by insurance companies the 
same way short-term readmissions are, they are detrimental to 
patients and place a similar burden on the healthcare system.  
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Pharmacist-driven interventions designed to reduce the use of 
high-risk medications have been developed to reduce 
medication-related adverse events(10) and hospital 
readmissions(11,12) among geriatric patients. A recent study 
completed at Vanderbilt University examined the effect of 
pharmacist counseling in patients with acute coronary 
syndrome and decompensated heart failure on emergency 
department use and 30-day readmission rates and found a 
beneficial effect of the intervention in patients with low health 
literacy scores(13). Pharmacists, as key members of an 
interprofessional health care team, are well positioned to have 
a positive impact on medication and polypharmacy. 
 
High utilizers, because of frequent readmissions, fragmented 
care, and negative social determinants of health, are at risk for 
complex medication regimens that may include high-risk or 
unsafe medications. The oldest patients in this population are 
at even greater risk, as they may suffer from unexpected side 
effects of medications or have additional difficulty managing a 
complex regimen. Here, we describe a pilot study evaluating 
the impact of a pharmacist-based intervention to improve 
medication safety at hospital discharge on readmission rates 
among geriatric high-utilizer patients. 
 
Methods 
Study Design 
This is a quasi-experimental pilot study of a pharmacist-based 
intervention to improve medication safety and reduce hospital 
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readmissions in a population of geriatric patients with a history 
of frequent admissions to the hospital.  
 
Patient Population 
Patients were eligible for inclusion in the study if they were 65 
years old or older, had been admitted to Grady Health System 
(GHS) three or more times in 2015 or 2016, and were currently 
admitted to an internal medicine service at GHS. Patients were 
not eligible if they did not speak English, were incarcerated, 
were unable to consent for the study due to illness or dementia 
and did not have family or a medical decision maker available, 
or if they were planned to discharge from the hospital to a 
nursing home or hospice. Additionally, patients were not 
eligible if they were admitted to GHS’s Acute Care of the Elderly 
(ACE) unit during the hospitalization in which they would be 
enrolled in the study. This is a multidisciplinary team focused 
on preventing decline of geriatric patients while hospitalized 
and provides a comprehensive post-discharge follow up 
plan(14). The ACE unit only had ten beds at the time of this 
research, so a fraction of all admitted elderly patients were not 
eligible for this reason. 
 
Patient Identification and Enrollment 
Patients were identified by reviewing a list of all patients 
admitted to internal medicine teams during the prior day. If on 
chart review a patient met inclusion criteria and there were no 
exclusion criteria identified, the medical team was notified of 
the patient’s appropriateness for inclusion. The patient was 
then approached for enrollment by a study team member. 
Verbal and written consent was obtained from the patient or 
their medical decision maker. All study procedures and 
consents were approved by the Emory University Institutional 
Review Board and the Grady Health System Research Oversight 
Committee. 
 
Baseline data was obtained from the participant’s electronic 
medical record (EMR), Epic Systems (Verona, WI). This included 
demographics (name, medical record number, date of birth, 
sex), medical history (from progress notes including the history 
and physical and discharge summaries), past hospital 
admissions, and medications prescribed prior to hospital 
admission. The Charlson Comorbidity Index, a tool designed to 
measure the longitudinal risk of mortality based on comorbid 
conditions in longitudinal studies, was calculated based on 
patient’s medical history(15,16). All data was stored in 
RedCap(17). 
 
Medication Appropriateness Index & Beers Criteria 
The Medication Appropriateness Index (MAI) is a 10-question 
tool developed to assess the level of inappropriateness of a 
medication(18,19). The score ranges from 0-18, with 0 
representing an appropriate medication and 18 representing a 
maximally inappropriate medication. It has been used in a 
number of different research settings and has good inter-rater 
reliability between pharmacists and physicians(10). The MAI 
questions are listed in the supplemental material (Table S1).  
 
The Beers Criteria is a list of medications deemed potentially 
inappropriate in elderly patients that is published by the 
American Geriatrics Society(20). At the time of this study, the 
Beers Criteria was most recently updated in 2015. 
 
Intervention 
On the day of discharge, an email was sent to the medical team 
to remind them to contact one of the study pharmacists once 
the discharge medication reconciliation had been completed. 
Once the pharmacist was notified, they reviewed the discharge 
medication list and calculated the MAI for each medication and 
reviewed for Beers Criteria. Any medication identified as 
potentially high-risk or inappropriate, based on their MAI score 
or Beers Criteria, was flagged by the pharmacist and shared 
with the team. Recommendations were made to the primary 
team by the pharmacist but no decisions about stopping or 
changing medications were made by the research team. The 
pharmacists reviewed the EMR after discharge to record which 
medications, if any, were changed. 
 
Outcomes 
The primary outcome of this study was the number of hospital 
readmissions in the year following the intervention compared 
to the number of admissions they had in the calendar year prior 
to enrollment (2015 or 2016). Secondary outcomes included 
the effect of the pharmacy intervention on the overall use of 
high-risk medications in this population, and the change over 
the following year on the use of high-risk medications as 
defined by their MAI score and presence of Beers Criteria 
medications.  
 
Control Group 
Patients who were discharged without receiving the 
intervention were placed in the control group. They may not 
have received the intervention because the medical team 
forgot to alert the study team when the patient was leaving or 
the patient was discharged in the evening or on a weekend 
when the study team was not available. The patients who do 
not receive the intervention only had the baseline chart review 
and final follow-up data collected one year after the hospital 
admission during which they were enrolled.  
  
Intervention Group  
Participants who received the intervention were contacted via 
telephone at one month, three months, and six months after 
hospital discharge. A study team member contacted the 
participant and obtained a current medication list based on 
participant self-report. If the study team member was unable 
to reach the participant, two more attempts were made over 
the following one to two weeks before the follow-up encounter 
was closed. This duration was chosen so that the follow-up data 
collection occurred as close as possible to the intervals in the 
study while still giving the research team a variety of times and 
days of the week to contact the participant. 
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The medical charts of all study participants were reviewed one 
year after the hospital admission at which they were enrolled. 
Data collected from this chart review included current medical 
diagnoses, hospital admissions since enrollment in the study, 
current medications, and if the patient had died in the year 
since enrollment. 
 
Data Analysis 
All data analysis was performed in SAS 9.2 (Cary, NC). 
Medications were categorized into the following groups: 
neurologic, cardiac, gastrointestinal, endocrine, pulmonary, 
mental health/pain, renal/genitourinary, infectious diseases, 
and other. Chi-squared tests were performed on categorical 
variables, and t-tests were performed on continuous variables. 
One-way ANOVA was used to compare the number of 
admissions in the year prior to enrollment and the year after 
enrollment in the intervention and control groups for patients 
who were high-utilizers in 2015 and 2016; one-way ANOVA with 
a post-hoc Tukey test was used to compare number of 
medications and average MAI across time points. P was set at 
0.05. 
 
Results 
A total of 57 patients were included in the study. Baseline 
demographics are shown in Table 1. Among patients who were 
high-utilizers in 2015, patients in the intervention group had 
more admissions at baseline than those who were not in the 
intervention group. Patients who did not receive the 
intervention were more likely to have died in the year following 
the intervention than those who received the intervention. 
Notably, there was no statistically significant difference in the 
Charlson Comorbidity Index (CCI) between the two groups, 
although there was a trend towards the “no intervention” 
group having a higher CCI (p=0.079).  
 
Table 2 illustrates the change over time among patients in the 
intervention and no intervention groups. Figures 1 and 2 
illustrate that there was no difference in the primary outcome 
of number of admissions in the year following enrollment 
between the two groups.  
 
Table 3 lists the medications that were flagged by the 
pharmacist at discharge. A total of fourteen medications (5.9%) 
were flagged. The most common reason that the medication 
was flagged was that it was deemed not indicated by the 
pharmacist. Of the flagged medications, approximately 60% 
were changed by the medical team. The most common change 
made was for the medication to be discontinued. 
 
The average medication appropriateness index score and 
percent of Beers Criteria medications at the enrollment 
admission, discharge, and at the final follow-up one year after 
enrollment for all medications combined as well as each 
category of medications is listed in the supplemental material 
(Table S2), along with a list of the medications in each category 
(Table S3). Gastrointestinal medications had the highest 
average MAI score and the most Beers Criteria medications. 
Mental health and pain medications had significantly more 
Beers Criteria medications on admission among patients who 
did not receive the intervention, and their higher average MAI 
score trended towards significance. This difference became less 
pronounced at discharge and at the final follow-up.  
 
Discussion 
This study focused on a group of patients at risk for 
complications from high-risk medications: elderly patients in 
the 95th percentile for most admissions in a year at our 
hospital. While we did not see a statistically significant 
difference in the rate of hospital readmission at one year 
between the intervention and no intervention groups, there are 
still some important observations from this pilot study. 
 
The pharmacist intervention did not have a statistically 
significant impact on the average MAI of medications 
prescribed—in the intervention group the MAI on admission 
was 0.76 and at discharge was 0.58 (p=0.394); the control 
group’s MAI was also unchanged between admission and 
discharge (0.95 vs. 0.91, p=0.853). The medications that were 
flagged by the pharmacist at discharge and eventually 
discontinued were primarily medications that were not 
indicated—for example, vitamins without documented vitamin 
deficiencies. While these medications are not “high risk,” we 
argue that each additional medication in a regimen adds 
complexity and possibly confusion for patients like these who 
are often taking more than 10 medications. For example, the 
primary driver of increased MAI scores and frequency of Beers 
Criteria medications in the gastrointestinal medications group 
were proton pump inhibitors (PPI). It is unlikely that stopping 
these medications would prevent a readmission but removing 
them may decrease confusion and prevent short- and long-
term side effects(10). 
 
Interestingly, no medication received the highest MAI score of 
18. The highest score given was a medication that had been 
prescribed prior to admission in a patient with clear 
contraindications to the medication. Among medications 
prescribed during the study period, the category with the 
highest average MAI score was gastrointestinal medications. 
This was primarily driven by PPIs being prescribed without a 
stop date.  
 
Overall, the data indicate the medical teams were attentive to 
medication safety in this population, with only 14 medications 
identified by the pharmacists as inappropriate in the control 
group. Additionally, 35.4% of the medications in the pain and 
mental health category on the medication lists of patients in the 
control group on admission were on the Beers Criteria; this 
decreased to 27.9% at discharge without pharmacist 
intervention. However, this attention to the medication list 
could have been an unintended consequence of informing the 
medical teams that their patients were enrolled in the study. 
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Focusing on medication appropriateness instead of 
polypharmacy sets our approach apart. Many of our patients 
have significant medical problems that necessitate multiple 
medications. These medications may be required; only trying to 
reduce the number of medications the patient receives is not 
always the best approach. For patients in the intervention 
group, over time the average number of medications increased 
from 9.8 to 11.8 but average MAI decreased from 0.76 to 0.61, 
indicating that the patient population may be getting sicker but 
the medication use is appropriate. We hope that by making 
their overall medication list safer and more appropriate that 
they will only be on the medications that are absolutely 
necessary. 
 
There are several limitations of this study. Sample size is a major 
limitation and may be the reason we don’t have more 
significant results. Additionally, patients who were discharged 
on the weekends or in the evening did not receive the 
intervention because the pharmacist was not available at these 
times. There may be concern that these patients were less sick 
(hence why the medical team felt comfortable discharging 
them at these times), however, the CCI of patients in the control 
group was not statistically significantly different than the CCI of 
the intervention group, indicating that their baseline health was 
not that different. Finally, the use of patient self-report for the 
medication history at the various time points may have skewed 
the results at the one, three, and six-month phone calls, as 
patients may not be able to remember all of the medications 
they were prescribed. 
 
The problem of high-utilization is extremely complex, and no 
single intervention will be able to solve it. This project 
represents an initial step into developing targeted 
interventions for this population. This can be a challenging 
population to work with because of their multiple medical 
problems and overlying social issues. While inpatient 
interventions can be complicated, this may be a model that is 
effective for this population. The successes and challenges we 
encountered in this study will inform the development of future 
interventions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ethics Approval: The study was approved by the Emory 
Institutional Review Board and the Grady Health System 
Research Oversight Committee. All patients provided written 
and verbal consent prior to participating. 
 
Consent for Publication: Not applicable 
Availability of Data and Materials: The data generated during 
the current study are not publicly available due to patient 
confidentiality, but may be available from the corresponding 
author on reasonable request. 
 
Key Points 
1. Geriatric high-utilizers, because of frequent 
readmissions and fragmented care, are at risk for 
complex medication regimens that may include 
unsafe medications.  
2. This quasi-experimental pilot study of a pharmacist-
based intervention to improve medication safety and 
reduce hospital readmissions in a population of 
geriatric patients with a history of frequent 
admissions to the hospital did not show a difference 
in the rate of hospital readmissions between the two 
groups. 
3. The intervention did improve the average Medication 
Appropriateness Index score of patients at discharge. 
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Table 1: Demographics  
Intervention (n=21) No Intervention (n=36) p 
% Men  42.8% (9)  50% (18)  0.602 
Mean Age (range)  70.9 (66-86)  72.8 (65-86)  0.272  
Number of Admissions during year of high-
utilization  
2015: 5.3 (3-13)  
2016: 4.3 (3-9)  
2015: 3.8 (3-6)  
2016: 3.7 (3-6)  
0.045*  
0.258  
Average LOS (range)  2015: 3.9 (1.5-9.6)  
2016: 3.8 (2.0-7.2)  
2015: 3.8 (2.0-10.3)  
2016: 6.1 (2.0-17.3)  
0.856  
0.124  
Charlson Comorbidity Index Mean (range)  3.2 (1-7)  4.2 (1-9)  0.079  
% Discharged Home  85.7% (n=18)  77.7% (n=28)  0.517 
% died of patients whose outcomes are 
known  
5.6% (n=1)  29.0% (n=9)  0.049*  
*significant at p=0.05 
 
 
 
Table 2: Change Over Time of Number of Medications and Average Medication Appropriateness Index 
  Baseline Discharge 1 Month 3 Months 6 Months 1 Year 
(Final) 
p 
Intervention 
Number of Patients  21 21 13 7 10 20  
Average Number of Meds (range)  9.8 (0-18) 11.5 (4-18) 11.2 (4-16) 9.0 (6-13) 10.1 (2-19) 11.8 (7-19) 0.452 
Average MAI (score range)  0.76 (0-11) 0.58 (0-8) 0.41 (0-2) 0.77 (0-2) 0.82 (0-2) 0.62 (0-2) 0.601 
No Intervention 
Number of Patients 36 36  27  
Average Number of Meds (range)  12.0 (5-24) 12.3 (2-25) 11.8 (0-22) 0.769 
Average MAI (score range)  0.95 (0-16) 0.92 (0-5) 0.88 (0-2) 0.876 
 
 
 
Table 3: Medications Flagged by Pharmacists and Outcomes 
Medication Name Why was this medication flagged? What was the medication changed to? 
Albuterol Duplicate NA—no change 
Albuterol Duplicate NA—no change 
Albuterol-Ipratropium Ineffective Changed to alternate inhalers 
Atorvastatin Cost Changed to alternate statin 
Cyanocobalamin Not indicated Discontinued 
Dicyclomine Not indicated Discontinued 
Doxazosin Not indicated NA—no change 
Esomeprazole Duration NA—no change 
Esomeprazole Inappropriate duration NA—no change 
Folic Acid Not Indicated NA—no change 
Metoclopramide Not indicated Discontinued 
Ranitidine Duplicate  Discontinued 
Thiamine Not indicated Discontinued 
Trazodone Inappropriate dose Changed dose 
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Table S1: Medication Appropriateness Index Questions (18) 
 
Question Score 
Is there an indication for the drug? 3 
Is the medication effective for the condition? 3 
Is the dosage correct? 2 
Are the directions correct? 2 
Are the directions practical? 2 
Are there clinically significant drug-drug interactions? 2 
Are there clinically significant drug-disease/condition interactions? 1 
Is there unnecessary duplication with other drug(s)? 1 
Is the duration of therapy acceptable? 1 
Is this drug the least expensive alternative compared with others of equal utility? 1 
 
 
 
 
